Results 231 to 240 of about 24,350 (247)

USP38: an important regulatory factor in tumor malignant progression. [PDF]

Front Immunol
Li J, Zhong J, Ye J, Xiang Y, Yi Q, Zhu G, Deng S, Wang X.   +7 more
europepmc   +1 more source

Epigenetic Regulation of Immune Responses in Endocrine-Related Cancers and Its Role in Immunotherapy. [PDF]

Cancers (Basel)
Akyuz EM, Gultekin M, Ramage JM, Spendlove I, Jackson AM, Adhikaree J, Malecka AA.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Modeling LSD1-Mediated Tumor Stagnation

Bulletin of Mathematical Biology, 2021
LSD1 (KDMA1) has gained attention in the last decade as a cancer biomarker and drug target. In particular, recent work suggests that LSD1 inhibition alone reduces tumor growth, increases T cell tumor infiltration, and complements PD1/PDL1 checkpoint inhibitor therapy.
Jesse Milzman, Wanqiang Sheng, Doron Levy   +2 more
openaire   +3 more sources

Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1

Journal of Medicinal Chemistry, 2021
As a flavin adenine dinucleotide (FAD)-dependent monoamine oxidase, lysine specific demethylase 1 (LSD1/KDM1A) functions as a transcription coactivator or corepressor to regulate the methylation of histone 3 lysine 4 and 9 (H3K4/9), and it has emerged as a promising epigenetic target for anticancer treatment. To date, numerous inhibitors targeting LSD1
Xing-Jie Dai, Ying Liu, Lei-Peng Xue, Xiao-Peng Xiong, Ying Zhou, Yi-Chao Zheng, Hong-Min Liu   +6 more
openaire   +2 more sources

Discovery of acridine-based LSD1 inhibitors as immune activators targeting LSD1 in gastric cancer

European Journal of Medicinal Chemistry, 2023
LSD1 is overexpressed in various cancers and promotes tumor cell proliferation, tumor expansion, and suppresses immune cells infiltration and is closely associated with immune checkpoint inhibitors therapy. Therefore, the inhibition of LSD1 has been recognized as a promising strategy for cancer therapy.
Hui-Min Liu, Xiao-Peng Xiong, Jiang-Wan Wu, He-Xiang Chen, Ying Zhou, Shi-Kun Ji, Xing-Jie Dai, Yi-Chao Zheng, Hong-Min Liu   +8 more
openaire   +2 more sources

LSD1 Makes Fat Colorful

Trends in Endocrinology & Metabolism, 2017
The histone lysine-specific demethylase 1 (LSD1) is a new and important player in the regulation of brown fat identity and function. In a recent Cell Reports article, Duteil et al. show that LSD1 exerts its effects via regulation of specific histone marks as well as through association with co-repressor complexes.
Leon G, Straub, Christian, Wolfrum
openaire   +2 more sources

A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors

European Journal of Medicinal Chemistry, 2022
LSD1 was significantly over-expressed in several cancer types, and its aberrant overexpression was revealed to play a crucial role in the initiation and progression of cancer. Several LSD1 inhibitors that were discovered and developed so far were found to be effective in attenuating tumor growth in both in vivo and in vitro studies.
Jianshu Dong, Waqar Pervaiz, Bilal Tayyab, Dié Li, Lei Kang, Huimin Zhang, Huimin Gong, Xinli Ma, Jian Li, Clement Agboyibor, Yuefeng Bi, Hongmin Liu   +11 more
openaire   +2 more sources

Baicalin, a natural LSD1 inhibitor

Bioorganic Chemistry, 2016
Baicalin is one of the active ingredients in the skullcap, with a variety of pharmacological effects, such as blood pressure reduction, sedation, liver-protection, gallbladder-protection, anti-bacteria, and anti-inflammation. In our study, baicalin was first characterized as a LSD1 inhibitor with an IC50 of 3.01μM and showed strong LSD1 inhibitory ...
Yi-Chao, Zheng, Dan-Dan, Shen, Meng, Ren, Xue-Qi, Liu, Zhi-Ru, Wang, Ying, Liu, Qian-Na, Zhang, Li-Juan, Zhao, Li-Jie, Zhao, Jin-Lian, Ma, Bin, Yu, Hong-Min, Liu   +11 more
openaire   +2 more sources